Over 20 People Receive Lenacapavir PrEP as Eswatini Celebrates World AIDS Day
By Thokozani Mazibuko
Eswatini stepped confidently into a new era of HIV prevention as the long-awaited long-acting injectable PrEP, known as lenacapavir, was officially introduced during the World AIDS Day 2025 commemoration at Hhukwini Inkhundla.
The milestone launch, led by Prime Minister Russell Mmiso Dlamini and Minister of Health Mduduzi Matsebula, highlighted a major advancement in the country’s HIV response.
Lenacapavir, administered only twice a year, offers a discreet and convenient alternative to daily oral PrEP. Its long-acting nature is expected to ease many of the challenges individuals have faced with adherence, privacy, stigma and busy schedules.
Health officials confirmed that more than 20 people received the injection on Monday, signalling strong early interest and acceptance among the public.
Prime Minister described the rollout as a significant stride toward His Majesty King Mswati III’s vision of a healthier nation supported by modern health innovations.
He noted that expanding prevention options is crucial in meeting the needs of diverse groups, especially young people, adolescent girls and young women, and key populations who remain disproportionately vulnerable to HIV.
He emphasised that the new tool strengthens the country’s push toward achieving an AIDS-free Eswatini by 2030.
The scientific breakthrough behind lenacapavir has been widely celebrated globally. The injection,by blocking the virus from multiplying and establishing infection, offers highly effective protection with minimal clinic visits.
Minister Matsebula highlighted that lenacapavir addresses one of the biggest challenges associated with oral PrEP adherence by requiring only two doses per year.
Healthcare workers at the commemoration expressed optimism that the new injectable will reduce both client and facility burden. With fewer clinic visits required, health workers can dedicate more time to counselling, follow-up and reaching underserved communities.
This shift is expected to improve the overall quality of prevention services and deepen trust between communities and the health system.
Young people who attended the event welcomed the new option, saying it offers privacy and relief from the pressure of daily medication.
Many noted that stigma and fear of judgment often discourage them from accessing prevention services. A twice-yearly injection, they said, gives them more control and confidence in protecting themselves.
The introduction of lenacapavir also reinforces Eswatini’s position as a global leader in HIV control. The country has surpassed the UNAIDS 95–95–95 targets and continues to invest in innovations that strengthen its health response.
The government and its partners view the rollout as part of a broader strategy to widen HIV prevention choices, rather than replace existing methods.
Condoms, oral PrEP, behavioural interventions, community education and gender empowerment programmes will continue to play essential roles.
The Ministry of Health announced a phased rollout to ensure facilities are adequately prepared, healthcare workers trained and communities well informed.
Awareness campaigns will accompany the implementation to educate the public on eligibility, availability and safe use. Community leaders and youth groups endorsed the approach, urging continuous engagement to reach even the most remote areas.
A candle-lighting ceremony closed the commemoration, honouring lives lost to AIDS-related illnesses and reaffirming commitment to supporting those living with HIV.